title: [Determination of blood levels for oral anticancer drugs].
abstract: Oral tyrosine kinase inhibitors and mammalian target of rapamycin (mTOR) inhibitors are indicated in several types of cancer. They are usually administered at a fixed dose. In recent years, observational studies have reported on the wide variability in exposure to these new drugs, and the relationship between clinical response (efficacy and toxicity) and target plasma concentrations. Additionally, we are gaining insight into different food and drug interactions with these new drugs. On the basis of current drug monitoring, advice can be given on individual dosing of pazopanib in metastatic renal cell cancer (mRCC), sunitinib in mRCC and gastrointestinal stromal tumor (GIST), and imatinib in GIST.
authors.affiliation: Radboudumc, Nijmegen.
authors.forename: Nielka P
authors.initials: NP
authors.lastname: van Erp
authors.forename: Winette T A
authors.initials: WT
authors.lastname: van der Graaf
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D006801:Humans; D009369:Neoplasms / Q000097:blood* / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D020123:Sirolimus / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D020123:Sirolimus